Globus Medical has completed its acquisition of the US-based medical device company Nevro, broadening its market presence in musculoskeletal solutions.
The deal, which was initially announced in February 2025, involved the companies signing a definitive agreement.
Go deeper with GlobalData
Globus agreed to acquire Nevro’s complete shares for $5.85 each, culminating in a total equity value of roughly $250m.
Both companies’ boards of directors gave unanimous approval for this transaction.
Globus noted that this acquisition not only marks a significant expansion but a $2.5bn market opportunity, enhancing its product range in the neuromodulation sector.
The company also noted that it intends to discuss the acquisition closure and expected benefits of the expanded product offerings in its first quarter earnings conference in May.
Morgan Stanley & Co. and Wyrick Robbins Yates & Ponton provided financial and legal advisory services, respectively, to Globus.
Nevro was advised by BofA Securities and Latham & Watkins in financial and legal matters, respectively.
Globus focuses on addressing clinical needs in musculoskeletal care. It works across orthopaedic trauma, spine, biomaterials, joint reconstruction and enabling technologies, offering education and clinical backing.
Nevro’s HFX spinal cord stimulation platform (SCS) includes the Senza SCS system. It offers support services for chronic pain treatment of limbs and trunks, as well as painful diabetic neuropathy.
The company’s products are designed to offer “minimally invasive” treatment alternatives for individuals with chronic sacroiliac joint pain.
Globus Medical CEO and president Dan Scavilla said: “We are excited to begin the journey of accelerating market penetration of Nevro’s differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering from chronic pain.”
